About luye pharma group ltd - LYPHF
Luye Pharma Group Ltd. is an investment holding company, which engages in the developing, producing, marketing, and selling of pharmaceutical products. It operates through the following segments: Oncology Drugs, Cardiovascular System Drugs, Alimentary Tract and Metabolism Drugs, Central Nervous System Drugs, and Others. The company was founded on June 8, 1994 and is headquartered in Yantai, China.
LYPHF At a Glance
Luye Pharma Group Ltd.
Unit 601, Building 2, Phase 3
Guangzhou, Guangdong 510320
| Phone | 86-20-2820-485 | Revenue | 877.57M | |
| Industry | Pharmaceuticals: Major | Net Income | 86.08M | |
| Sector | Health Technology | 2025 Sales Growth | 4.195% | |
| Fiscal Year-end | 12 / 2026 | Employees | 5,221 | |
| View SEC Filings |
LYPHF Valuation
| P/E Current | 9.235 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 15.929 |
| Price to Sales Ratio | 1.563 |
| Price to Book Ratio | 0.611 |
| Price to Cash Flow Ratio | 4.99 |
| Enterprise Value to EBITDA | 6.108 |
| Enterprise Value to Sales | 2.024 |
| Total Debt to Enterprise Value | 0.759 |
LYPHF Efficiency
| Revenue/Employee | 168,084.862 |
| Income Per Employee | 16,486.341 |
| Receivables Turnover | 1.221 |
| Total Asset Turnover | 0.20 |
LYPHF Liquidity
| Current Ratio | 1.533 |
| Quick Ratio | 1.437 |
| Cash Ratio | 0.893 |
LYPHF Profitability
| Gross Margin | 65.916 |
| Operating Margin | 19.826 |
| Pretax Margin | 15.475 |
| Net Margin | 9.808 |
| Return on Assets | 1.966 |
| Return on Equity | 4.061 |
| Return on Total Capital | 2.36 |
| Return on Invested Capital | 3.44 |
LYPHF Capital Structure
| Total Debt to Total Equity | 58.592 |
| Total Debt to Total Capital | 36.945 |
| Total Debt to Total Assets | 28.689 |
| Long-Term Debt to Equity | 16.943 |
| Long-Term Debt to Total Capital | 10.683 |